Oral PDE-4 Inhibitor, OTEZLA, Approved for the Treatment of Plaque Psor
The first oral treatment in 25 years for patients in Japan with these diseas...
2016-12-23
文传商讯
Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung can
International survey showed high global EGFR testing rates prior to first-li...
2016-12-09
文传商讯
Clinically meaningful data for oral nintedanib in mesothelioma presente
Mesothelioma is a rare and difficult-to-treat cancer with no targeted treatm...
2016-12-09
文传商讯
Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-
Phase I/II trial findings add to growing body of data on acalabrutinib clini...
2016-12-06
文传商讯
New Data Show High Adherence Rates with Pradaxa (dabigatran etexilate)
New analysis of GLORIA™-AF Registry Program includes data from nearly ...
2016-12-06
文传商讯
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Tr
– Data will be presented in an oral session at the annual American Soc...
2016-12-06
文传商讯
NINLARO™ (ixazomib) Receives Conditional Approval from the Europe
Approval Based on TOURMALINE-MM1 Study Results, Which Demonstrated Statistic...
2016-11-29
文传商讯
Updated Phase III Results Reinforce Safety and Efficacy of Praxbind®
Idarucizumab immediately reversed the anticoagulant effect of dabigatran in ...
2016-11-17
文传商讯
Patient enrolment completed for RE-DUAL PCI study assessing dabigatran
Over 2,700 atrial fibrillation (AF) patients undergoing a percutaneous coron...
2016-11-16
文传商讯
Data on Early Onset of Efficacy for Oral OTEZLA (apremilast) in Active
ACTIVE trial in biologic-naïve patients met its primary endpoint, demon...
2016-11-16
文传商讯
